Korean biotech company Macrogen reported on Tuesday the receipt of the CE Mark for in-vitro diagnostic devices (CE-IVD) in Europe for the distribution of the Axen COVID-19 RT test kits into the European market, as well as several other countries that recognize the CE-IVD .
Macrogen said its COVID-19 test kit uses RT-PCR which confirms whether a person is infected with COVID-19 in just two hours, allowing a large number of tests to be performed quickly and effective. As the kit detects the ORF1ab and E genes, two genes related to COVID-19, it has a high level of precision and target detection. Thus, the test kit is more appropriately evaluated for COVID-19 trace-controlled patients.
Earlier, the company has successfully launched a clinical trial with its test kit, confirming 100% consistency in 20 samples, each with positive and negative groups.
In addition, Macrogen stated that it has received the export approval from the Korean Ministry of Food and Drug Safety as well as is currently awaiting US approval through the United States Food and Drug Administration (FDA).
Foresee Pharmaceuticals receives positive CHMP opinion for CAMCEVI 21 mg
Great Novel Therapeutics' GNTbm-38 approved by US FDA for Phase I trial
Johnson & Johnson reports US FDA approval of TECVAYLI plus DARZALEX FASPRO for RRMM
Airiver Medical's Airiver Pulmonary DCB receives US FDA Breakthrough Device Designation
Sanaregen receives FDA clearance for retinal degeneration clinical trial
Esperion to acquire Corstasis, expanding cardiovascular portfolio
ReviR Therapeutics doses first participant in First-in-Human Phase 1 clinical trial of RTX-117
BD receives FDA clearance for Surgiphor 1000mL irrigation system
United Therapeutics' ralinepag reduces risk of clinical worsening in pivotal PAH study
FDA accepts rusfertide NDA and grants priority review for polycythemia vera